Health Care • Biotechnology: Pharmaceutical Preparations
$3.44 ▲ +0.09
(+2.69%)
MKT CAP: $366.9M • VOL: 1.61M
52W L $2 52W H $8
ROARABLE / RQD
D • 44/100
PIOTROSKI
1 / 9
RLMD // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 |
|---|---|---|
| Revenue (Total Sales) | $0 | $0 |
| YoY Revenue Growth % | — | — |
| Gross Profit | — | — |
| Gross Margin % | — | — |
| Research & Development (R&D) | — | — |
| Operating Income (EBIT) | -$59.1M | -$83.9M |
| Operating Margin % | — | — |
| Net Income (GAAP) | $0 | $0 |
| EBITDA (Normalized) | — | — |
| Diluted EPS ($/sh) | — | — |
| Operating Cash Flow (OCF) | -$45.8M | -$51.8M |
| Capital Expenditures (CapEx) | — | — |
| Free Cash Flow (FCF) | -$45.8M | -$51.8M |
| FCF Margin % | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% |
| Cash & Short-Term Equivalents | $3.5M | $3.9M |
| Total Debt (Short + Long Term) | — | — |
| Total Stockholders' Equity | $86.5M | $35.5M |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RLMD.